Evaluation of the physical properties and stability of two lipid drug delivery systems containing mefloquine
Stability data is used to determine the change the product has undergone over a certain time period at specific temperatures. In the present study, the physical stability characterized by size, pH and entrapment efficacy of mefloquine loaded liposomes and Pheroid™ vesicles were investigated. Size wa...
Saved in:
| Published in: | International journal of pharmaceutics Vol. 409; no. 1; pp. 209 - 215 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Amsterdam
Elsevier B.V
16.05.2011
Elsevier |
| Subjects: | |
| ISSN: | 0378-5173, 1873-3476, 1873-3476 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Stability data is used to determine the change the product has undergone over a certain time period at specific temperatures. In the present study, the physical stability characterized by size, pH and entrapment efficacy of mefloquine loaded liposomes and Pheroid™ vesicles were investigated. Size was accurately determined by flow cytometry. Entrapment efficacy, after unentrapped drug was removed was successfully determined by UV-spectrophotometry. The formulations contained 0.5% (m/v) mefloquine and results showed that mefloquine interfered with the formation of lipid bilayer of the liposomes. Liposomes increased in size from 5.22
±
0.03
μm to 9.71
±
1.11
μm with accelerated stability and large aggregates were observed. A notable difference in stability testing of Pheroid™ vesicles was seen with no significant increase in size. Entrapment efficacy of 68.72
±
0.04% (5
°C), 67.45
±
2.92% (25
°C) and 67.45
±
2.92% (30
°C) were obtained at the different storage conditions. With these findings the mefloquine loaded Pheroid™ vesicles are stable and should be used investigated for the possible increase in efficacy and bioavailability and decrease toxicity. |
|---|---|
| Bibliography: | http://dx.doi.org/10.1016/j.ijpharm.2011.01.050 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| ISSN: | 0378-5173 1873-3476 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2011.01.050 |